Abstract: CNA biomarkers can include nucleic acid sequences that are present in circulating nucleic acids obtained from circulatory systems of a population known to have cancer, but that are rarely present, if at all, in circulating nucleic acids obtained from circulatory systems of a control population. Information is received describing one or more sequences obtained from circulating nucleic acids in a population known to have cancer. Information is also received describing one or more sequences obtained from circulating nucleic acids in a control population. A cluster analysis within a predetermined portion of a genome uses the one or more sequences in the circulating nucleic acids obtained from the population known to have cancer and the one or more sequences in the circulating nucleic acids obtained from the control population. Information is generated identifying one or more biomarkers for the cancer based on a cluster search within results of the cluster analysis.

Abstract: The invention provides methods and reagents for diagnosing prostate cancer that are based on the detection of biomarkers in the circulating nucleic acids from a patient to be evaluated.

Abstract: The invention provides methods and reagents for diagnosing breast cancer that are based on the detection of biomarkers in the circulating nucleic acids from a patient to be evaluated.

Abstract: This invention provides methods, compositions, and kits relating to detecting donor cell-free DNA in the circulation of a transplant recipient for the early identification of transplant rejection or for detection of damage to transplant cells.

Abstract: This invention provides a method of quantifying chimeric DNA in a cell-free DNA sample.

Abstract: CNA biomarkers can include nucleic acid sequences that are present in circulating nucleic acids obtained from circulatory systems of a population known to have cancer, but that are rarely present, if at all, in circulating nucleic acids obtained from circulatory systems of a control population. Information is received describing one or more sequences obtained from circulating nucleic acids in a population known to have cancer. Information is also received describing one or more sequences obtained from circulating nucleic acids in a control population. A cluster analysis within a predetermined portion of a genome uses the one or more sequences in the circulating nucleic acids obtained from the population known to have cancer and the one or more sequences in the circulating nucleic acids obtained from the control population. Information is generated identifying one or more biomarkers for the cancer based on a cluster search within results of the cluster analysis.

Abstract: The invention provides methods and reagents for diagnosing prostate cancer that are based on the detection of biomarkers in the circulating nucleic acids from a patient to be evaluated.

Abstract: The invention provides methods and reagents for diagnosing breast cancer that are based on the detection of biomarkers in the circulating nucleic acids from a patient to be evaluated.

Abstract: The invention provides methods and reagents for identifying personalized tumor biomarkers for a patient that has a solid tumor and methods of using such biomarkers to monitor patient responses to therapeutic treatments.

Abstract: The invention provides methods and reagents for identifying personalized tumor biomarkers for a patient that has a solid tumor and methods of using such biomarkers to monitor patient responses to therapeutic treatments.

Abstract: The invention provides methods and reagents for diagnosing prostate cancer that are based on the detection of biomarkers in the circulating nucleic acids from a patient to be evaluated.

Abstract: The invention provides methods and reagents for diagnosing prostate cancer that are based on the detection of biomarkers in the circulating nucleic acids from a patient to be evaluated.

Abstract: The invention provides methods and reagents for diagnosing breast cancer that are based on the detection of biomarkers in the circulating nucleic acids from a patient to be evaluated.

Abstract: This invention provides sensitive nucleic acid hybridization assay methods for the detection of target animal nucleic acids in a biological sample, such as acellular fluids. The methods are particularly useful in early diagnosis of animal diseases, particularly chronic illnesses.

Abstract: The present invention provides a method of detecting abnormal serum nucleic acid profiles to assess the risk of a transmissible spongiform encephalopathy, e.g., BSE.

Abstract: The present invention provides a method of detecting abnormal circulating nucleic acid profiles to assess the risk of Creutzfeldt-Jakob Disease.

Abstract: The present invention provides a method of detecting abnormal serum nucleic acid profiles to assess the risk of a transmissible spongiform encephalopathy, e.g., BSE.

Abstract: This invention provides sensitive nucleic acid hybridization assay methods for the detection of target animal nucleic acids in a biological sample, such as acellular fluids. The methods are particularly useful in early diagnosis of animal diseases, particularly chronic illnesses.

Abstract: This invention provides sensitive nucleic acid hybridization assay methods for the detection of target animal nucleic acids in a biological sample, such as acellular fluids. The methods are particularly useful in early diagnosis of animal diseases, particularly chronic illnesses.

Abstract: This invention provides sensitive nucleic acid hybridization assay methods for the detection of target human nucleic acids in a biological sample, such as acellular fluids. The methods are particularly useful in early diagnosis of chronic illnesses.